Kursinformation
Aktuelle News
News Funktionen
Weitere Funktionen
11 November 2019
ORYX GmbH & Co. KG
ORYX Confirms ParvOryx Mode of Action in Tumor Explant Model
4 November 2019
ORYX GmbH & Co. KG
ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx
30 Oktober 2019
ORYX GmbH & Co. KG
ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer
16 Mai 2018
ORYX GmbH & Co. KG
ORYX to Present Positive Clinical Data for Oncolytic Virus ParvOryx in Combination with Immune Modulators at CIMT Annual Meeting 2018
6 November 2017
ORYX GmbH & Co. KG
ORYX: Positive data from Phase I/IIa clinical trial in glioblastoma with oncolytic virus ParvOryx published in peer-reviewed journal, Molecular Therapy
6 September 2017
ORYX GmbH & Co. KG
ORYX to present positive clinical data with oncolytic virus ParvOryx in combination with immune activators at the Third CRI-CIMT-EATI-AACR Conference